Alignment Healthcare, Inc.

Alignment Healthcare maintains a capital structure characterized by significant leverage, with a debt-to-equity ratio of 1.56 and total liabilities of $1.05 billion against total equity of $206.9 million. The balance sheet holds $705.6 million in cash and equivalents, providing a current ratio of 1.58, which supports short-term liquidity despite the high leverage profile. Long-term debt stands at $323.6 million, with no short-term debt obligations recorded in the latest period. The market capitalization is approximately $3.93 billion, implying a price-to-book ratio of 23.07, which suggests the market values the company significantly above its tangible book value.

Profitability metrics indicate thin margins, with operating income of $15.5 million and net income of $11.4 million on revenue of $1.24 billion for Q1 2026. Return on equity is negative at -0.35%, and return on assets is -0.06%, reflecting the capital-intensive nature of the insurance business and the impact of high leverage on returns. The EV/EBITDA multiple is 78.09, indicating a high valuation relative to earnings, while the EV/Revenue ratio is 0.89. These figures suggest that while the company generates substantial cash flow from operations ($128.7 million), net profitability remains constrained by the scale of liabilities and operational costs.

Alignment Healthcare, Inc. (ALHC) has entered the scope of this analysis, marking the first available data point for the ticker with no prior basis for computing material changes. The company currently maintains a shareholder base comprising 34 top holders, though it lacks coverage from analysts and is not included in any major indices. This baseline profile suggests a niche or emerging market presence where institutional visibility is still developing. Recent activity highlights significant shifts in ownership among specific investors. Investor ID 587 executed a major modification to their position, initially increasing their holdings from 236 shares to 11,209 shares, valued at approximately $0.20 million. However, subsequent signals indicate a reversal of this activity, with the same investor reducing their stake back to 236 shares. These rapid, major-severity adjustments in share count occurred within a short window in late June and early July 2026, suggesting active trading or repositioning by this entity. Concurrently, a new notable holder, Investor ID 486, added a position of 120,000 shares to their portfolio. This addition, valued at roughly $0.17 million, represents a fresh entry into the shareholder base as of the March 31, 2026 reporting period. The emergence of this new holder contrasts with the volatile activity of Investor ID 587, indicating diverse investor interest despite the company's limited analyst coverage. The significance of these movements lies in the concentration of ownership changes among a small number of identified investors. With no analyst estimates or index memberships to provide broader market context, these holder changes offer the primary signal of market sentiment for ALHC. The juxtaposition of a new substantial entry against the rapid accumulation and divestment by another investor underscores the dynamic nature of the company's current shareholder structure.

Revenue grew at a 22.5% compound annual rate from FY2023 to FY2025, demonstrating strong top-line expansion.

The company achieved positive operating income of $14.8 million in FY2025, marking a significant turnaround from prior losses.

Free cash flow turned positive to $113.1 million in FY2025, indicating improved operational cash generation capabilities.

Net income narrowed significantly to a near-breakeven loss of $0.7 million in FY2025, showing rapid profitability convergence.

Liquidity risk is assessed as low, suggesting the company maintains sufficient short-term financial stability.

The company faces high dilution risk, which could negatively impact existing shareholder value and earnings per share.

Debt-to-equity ratio of 1.56 is significantly higher than the 0.21 median for the insurance cohort.

Revenue $1.24B; Operating income $15.5M.

• ▍Revenue $1.24B
• ▍Operating income $15.5M
• ▍Net margin 0.9%

Revenue $2.94B; Operating income $25.0M.

• ▍Revenue $2.94B
• ▍Operating income $25.0M
• ▍Net margin 0.4%

Revenue $1.94B; Operating income $17.4M.

• ▍Revenue $1.94B
• ▍Operating income $17.4M
• ▍Net margin 0.3%

Revenue $3.95B; Operating income $14.8M.

• ▍Revenue $3.95B
• ▍Operating income $14.8M
• ▍Net margin -0.0%

Revenue $2.70B; Operating income -$101.6M.

• ▍Revenue $2.70B
• ▍Operating income -$101.6M
• ▍Net margin -4.7%

Revenue $2.70B; Operating income -$101.6M.

• ▍Revenue $2.70B
• ▍Operating income -$101.6M
• ▍Net margin -4.7%

Revenue $1.80B; Operating income -$127.8M.

• ▍Revenue $1.80B
• ▍Operating income -$127.8M
• ▍Net margin -8.2%

Revenue $1.82B; Operating income -$127.8M.

• ▍Revenue $1.82B
• ▍Operating income -$127.8M
• ▍Net margin -8.1%